We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
-2.21%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$704M
AUM Growth
-$99.5M
Cap. Flow
+$205M
Cap. Flow %
29.06%
Top 10 Hldgs %
90.93%
Holding
52
New
12
Increased
3
Reduced
15
Closed
20

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$23.5M
2
CCRN
Cross Country Healthcare
CCRN
+$1.72M
3
CFRX
ContraFect Corporation
CFRX
+$904K
4
FORA
Forian
FORA
+$188K

Top Sells

Rank Stock Value
1
VIR icon
Vir Biotechnology
VIR
+$12.6M
2
AVIR icon
Atea Pharmaceuticals
AVIR
+$10.8M
3
YMAB
Y-mAbs Therapeutics
YMAB
+$9.01M
4
GH icon
Guardant Health
GH
+$8.75M
5
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$7.84M

Sector Composition

Rank Sector Weight
1 Healthcare 96.75%
2 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
26
Biogen
BIIB
$30.7B
$579K 0.08%
2,412
– –
CNC icon
27
PUT
Centene
CNC
$32.5B
$531K 0.08%
+416,300
New +$30.5M
DMTK
28
PUT
DELISTED
DermTech, Inc. Common Stock
DMTK
$425K 0.06%
+250,000
New +$6M
PTIX
29
DELISTED
Performance Technologies
PTIX
$416K 0.06%
5,362
-3,567
-40% -$363K
PACB icon
30
PUT
Pacific Biosciences
PACB
$370M
$126K 0.02%
+67,000
New +$1.62M
MOTS
31
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$49K 0.01%
353
-9,472
-96% -$1.64M
AGEN
32
PUT
Agenus
AGEN
$290M
$22K ﹤0.01%
+15,198
New +$1.2M
AGEN
33
CALL
Agenus
AGEN
$290M
– –
-5,095
Closed -$53K
AMRN
34
Amarin Corp
AMRN
$303M
– –
-41,920
Closed -$4.28M
AVIR icon
35
Atea Pharmaceuticals
AVIR
$420M
– –
-309,126
Closed -$10.8M
BCRX icon
36
CALL
BioCryst Pharmaceuticals
BCRX
$2.4B
– –
-150,000
Closed -$176K
BDSX icon
37
Biodesix
BDSX
$248M
– –
-9,042
Closed -$1.49M
GH icon
38
Guardant Health
GH
$22.6B
– –
-70,000
Closed -$8.75M
LLY icon
39
CALL
Eli Lilly
LLY
$1.06T
– –
-100,000
Closed -$680K
MDGL icon
40
CALL
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-63,000
Closed -$426K
MDGL icon
41
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-38,500
Closed -$3.07M
OPK icon
42
CALL
Opko Health
OPK
$1.02B
– –
-473,800
Closed -$145K
PACB icon
43
CALL
Pacific Biosciences
PACB
$370M
– –
-43,700
Closed -$50K
PFE icon
44
CALL
Pfizer
PFE
$153B
– –
-750,000
Closed -$98K
QQQ icon
45
PUT
Invesco QQQ Trust
QQQ
$484B
– –
-300,000
Closed -$895K
SEM
46
CALL
DELISTED
Select Medical
SEM
– –
-48,442
Closed -$193K
SEM
47
DELISTED
Select Medical
SEM
– –
-277,802
Closed -$5.41M
VIR icon
48
CALL
Vir Biotechnology
VIR
$1.49B
– –
-383,700
Closed -$1.2M
XBIT icon
49
XBiotech
XBIT
$69.2M
– –
-350,000
Closed -$4.56M
YMAB
50
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-315,642
Closed -$9.01M
1
2
3

Similar funds

EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM
CWA
Clearview Wealth Advisors Salem, Oregon $158M AUM 14.25% 1-Year Est. Return
SW
Schulz Wealth Mansfield, Texas $156M AUM 13.29% 1-Year Est. Return

Oracle Investment Management's Q4 2021 Portfolio in Review

As of Q4 2021, Oracle Investment Management held 52 positions worth $704M, down 12% from $803M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Oracle Investment Management deployed $205M of net new capital in Q4 2021, opening 12 new positions and adding to 3 existing holdings. Its largest new stake was Pfizer: 475,000 shares worth $28M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Energy.

On the sell side, the largest reduction was Vir Biotechnology, an estimated $12.6M trimmed.

  • Oracle Investment Management's largest Q4 2021 buy was Pfizer: 475,000 shares worth $28M.
  • Oracle Investment Management added most to ContraFect Corporation in Q4 2021, an estimated $904K increase.
  • Oracle Investment Management's biggest Q4 2021 reduction was Vir Biotechnology, cutting an estimated $12.6M.
  • Oracle Investment Management fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $10.8M.
  • Oracle Investment Management's ten largest holdings make up 91% of its $704M portfolio in Q4 2021.
  • Oracle Investment Management opened 12 new positions and closed 20 in Q4 2021.
  • Oracle Investment Management's portfolio value fell 12% quarter-over-quarter to $704M.

Based on Oracle Investment Management's 13F filing for Q4 2021, filed 14 Feb 2022.